Base de dados : MEDLINE
Pesquisa : D12.776.861.249 [Categoria DeCS]
Referências encontradas : 223 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 23 ir para página                         

  1 / 223 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28038704
[Au] Autor:Yang Y; Lu S; Zeng W; Xie S; Xiao S
[Ad] Endereço:Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China, 541000.
[Ti] Título:GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
[So] Source:Ann Diagn Pathol;26:1-5, 2017 Feb.
[Is] ISSN:1532-8198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:GATA3 has been recognized as the novel marker for identifying primary and metastatic breast carcinomas, consistently showing that GATA3 was significantly more sensitive than traditional markers gross cystic disease fluid protein 15 (GCDFP15) and mammaglobin (MGB). However, clinically useful groups of breast carcinomas status were not identified, which were determining appropriate treatment strategy, affecting the prognosis. In this study, we undertook a comparative study of the marker GATA3 and GCDFP15 and MGB in clinically useful groups of paired primary and metastatic breast cancer. We retrieved 64 cases of matched primary and metastatic breast cancer from the surgical pathology archive at our institution. According to the emerging 2015 St. Gallen Consensus, the clinically useful groups were divided into ER and/or PR (+), HER2 (-), abbreviated as A; ER and/or PR (+), HER2 (+), abbreviated as B; ER and PR (-), HER2 (+), abbreviated as C; ER, PR and HER2 (-), abbreviated as D; each group contained 16 cases (n=16). Tissue microarrays were created, with three 1-mm punch specimens from each case. The tissue microarrays were cut at 4-µm thickness and stained with monoclonal antibodies to GATA3, GCDFP15, and MGB. Staining intensity (0-3+) and extent (0%-100%) were scored with an H-score calculated (range, 0-300). Sensitivities by varying H-score cutoffs (any; ≥50; ≥150) for a positive result in the clinically useful groups of matched primary or metastatic breast cancer among GATA3, GCDFP15, and MGB. GATA3 was significantly more sensitive than GCDFP15 and MGB A and B groups (P<.05) rather than C and D groups (P>.05). However, GATA3 in conjunction with GCDFP15 and MGB detection could improve the sensitivity of C group (P<.05) rather than D group (P>.05). Significantly, good coincidence was observed between primary and metastatic tumor GATA3 expression (κ value = 0.826 >0.75) as compared with the coincidence of GCDFP15 (κ value =0.492 <0.75) and MGB (κ value =0.593 <0.75) (both P<.05). In conclusion, GATA3 expression did not show the same sensitivity for the clinically useful groups of breast cancer. GATA3 expression is positively correlated with ER-positive, PR-positive, and HER2-positive carcinomas. In addition, the matched primary and metastatic tumor expression of GATA3 shows good coincidence. We propose the careful selection of GATA3 for identifying hormone receptor negativity of breast cancer, especially in the case of triple-negative breast cancer.
[Mh] Termos MeSH primário: Neoplasias da Mama/metabolismo
Proteínas de Transporte/metabolismo
Fator de Transcrição GATA3/metabolismo
Glicoproteínas/metabolismo
Mamoglobina A/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/diagnóstico
Neoplasias da Mama/patologia
Neoplasias da Mama/secundário
Feminino
Seres Humanos
Imuno-Histoquímica/métodos
Receptores Estrogênicos/metabolismo
Análise Serial de Tecidos/métodos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (GATA3 Transcription Factor); 0 (GATA3 protein, human); 0 (Glycoproteins); 0 (Mammaglobin A); 0 (PIP protein, human); 0 (Receptors, Estrogen); 0 (SCGB2A2 protein, human)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170101
[St] Status:MEDLINE


  2 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27406050
[Au] Autor:Smith GJ; Hodges E; Markham H; Zhang S; Cutress RI
[Ad] Endereço:Department of Molecular Pathology, University Hospital Southampton, Southampton, UK.
[Ti] Título:Evaluation of the Metasin assay for intraoperative assessment of sentinel lymph node metastases in breast cancer.
[So] Source:J Clin Pathol;70(2):134-139, 2017 Feb.
[Is] ISSN:1472-4146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: Sentinel lymph node (SLN) biopsy is the preferred surgical technique for staging the axilla in clinically node-negative breast cancer. Accurate intraoperative staging allows for the immediate performance of an axillary clearance in node-positive patients. We assessed the Metasin assay for the intraoperative analysis of SLNs in a prospective evaluation of 250 consecutive patients undergoing intraoperative SLN analysis at the Breast Unit, University Hospital, Southampton, UK. METHODS: Metasin uses a quantitative reverse transcription PCR to detect two markers of metastasis: cytokeratin 19 (CK19) an epithelial marker and mammaglobin (MGB) a breast specific marker. Metasin results were compared with the results from routine paraffin block histopathology. RESULTS: Metasin was robust, with a failure rate of <1%, and demonstrated excellent accuracy and reproducibility. The average turnaround time for the Metasin assay was 42 min, the largest variable being the number of nodes assayed. A total of 533 SLNs were evaluated with 75 patients testing positive for MGB and/or CK19. Based on the analysis of individual SLNs, the overall concordance between Metasin and histology was 92.3% (sensitivity 88.7%, specificity 92.9%). When adjusted for tissue allocation bias, the concordance was 93.8% (sensitivity 89.8%, specificity 94.6%). In this evaluation, 57/250 patients (23%) proceeded to axillary clearance based on Metasin results and were considered spared a second operative procedure. CONCLUSIONS: Metasin has proven to be an accurate, reproducible and reliable laboratory test. The analysis time is acceptable for intraoperative use, and in comparison to routine histology demonstrates acceptable concordance, sensitivity and specificity.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Mama/patologia
Metástase Linfática/patologia
Linfonodo Sentinela/patologia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/genética
Biomarcadores Tumorais/metabolismo
Mama/metabolismo
Neoplasias da Mama/genética
Neoplasias da Mama/metabolismo
Neoplasias da Mama/cirurgia
Feminino
Seres Humanos
Período Intraoperatório
Queratina-19/genética
Queratina-19/metabolismo
Metástase Linfática/genética
Mamoglobina A/genética
Mamoglobina A/metabolismo
Monitorização Intraoperatória
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Linfonodo Sentinela/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Keratin-19); 0 (Mammaglobin A)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160714
[St] Status:MEDLINE
[do] DOI:10.1136/jclinpath-2016-203728


  3 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27563000
[Au] Autor:Bozhenko VK; Kharchenko NV; Vaskevich EF; Kudinova EA; Oorzhak AV; Rozhkova NI; Trotsenko ID
[Ad] Endereço:Russian Scientific Center of Roentgenoradiology, Moscow, Russia.
[Ti] Título:[Mammaglobin in peripheral blood and tumor in breast cancer patients].
[Ti] Título:Mammaglobin v perifericheskoi krovi i opukholi pri rake molochnoi zhelezy..
[So] Source:Biomed Khim;62(4):453-7, 2016 May.
[Is] ISSN:2310-6972
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Currently, no molecular biological markers do exist for early diagnosis of breast cancer. One of the possible candidates for the marker of early breast cancer is mammaglobin (MGB1) or SCGB2A2 (secretoglobin, family 2A, member 2), characterized by the maximal expression level in early breast cancer. Using the RT-PCR method MGB1 mRNA expression was examined in 57 tumor tissue samples and 57 samples of morphologically non-malignant tissue (MNT) of breast cancer (BC) patients. Specificity and sensitivity of the MGB1 mRNA assay in peripheral blood of BC patients was evaluated by nested PCR. 169 blood samples (from 95 BC patients, 22 from patients with benign breast tumors, 28 from patients with tumors of other localizations, and 24 samples from healthy donors) have been analyzed. MGB1 expression was significantly higher in BC tissue samples compared to MNT (p=0.0019). The maximal expression level was in the samples T1 (p=0.013), stage I BC (p=0.037), GI (p=0.0019). The MGB1 expression positively correlated with expression of estrogen (p = 0,034) and progesterone (p=0.0004) receptors. Sensitivity and specificity of the MGB1 mRNA assay in peripheral blood were 60.6% and 92.3%, respectively. Expression of MGB1 was higher in BC than MNT and it decreased during BC progression. The sensitivity and specificity of the MGB1 mRNA assay may be used as an additional diagnostic method.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Neoplasias da Mama/sangue
Mamoglobina A/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/genética
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/metabolismo
Neoplasias da Mama/patologia
Estudos de Casos e Controles
Feminino
Seres Humanos
Mamoglobina A/genética
Mamoglobina A/metabolismo
Meia-Idade
RNA Mensageiro/sangue
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Receptores Estrogênicos/genética
Receptores Estrogênicos/metabolismo
Receptores de Progesterona/genética
Receptores de Progesterona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Mammaglobin A); 0 (RNA, Messenger); 0 (Receptors, Estrogen); 0 (Receptors, Progesterone); 0 (SCGB2A2 protein, human)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160827
[St] Status:MEDLINE
[do] DOI:10.18097/PBMC20166204453


  4 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27278284
[Au] Autor:Liu B; Cui J; Sun J; Li J; Han X; Guo J; Yi M; Amizuka N; Xu X; Li M
[Ad] Endereço:Department of Bone Metabolism, School of Stomatology, Shandong University, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, Shandong 250012, P.R. China.
[Ti] Título:Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells.
[So] Source:Mol Med Rep;14(2):1099-106, 2016 Aug.
[Is] ISSN:1791-3004
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:The aim of the present study was to investigate the expression of matrix metalloproteinase (MMP)9 and MMP2, and their potential roles in bone metastasis nests using a well-standardized model of breast cancer bone metastasis in nude mice. BALB/c nu/nu mice (5-week-old; n=10) were subjected to intracardiac injection of MDA-MB-231 human breast cancer cells. After 4 weeks, the mice exhibiting radiolucent lesions in tibiae were sacrificed, and the tibiae were removed for histochemical analysis. The gene expression of MMP2 and MMP9 in the tumor cells, metaphysis and diaphysis of normal BALB/c nu/nu mice were determined using reverse transcription-polymerase chain reaction analysis. The metastatic tumor tissue occupied almost the entire bone marrow cavity. Numerous tartrate-resistant acid phosphatase-positive osteoclasts were found in the metastasized lesions. The invaded tumor cells positive for mammaglobin 1 exhibited different proliferation activities and apoptosis between the metaphysis and diaphysis. Proliferating cell nuclear antigen was expressed at high levels in the metaphyseal area, whereas TdT-mediated dUTP nick-end labeling (TUNEL)-positive cells were more evident in the diaphysis area. Of note, MMP9 was expressed predominantly in the proliferating cell nuclear antigen­positive area, whereas the expression of MMP2 was observed predominantly in the diaphysis, which had more TUNEL­positive cells. Taken together, the results suggested that MMP9 and MMP2 may have their own importance in extracellular matrix degradation and trabecular bone damage in different zones of bone metastasis, including the metaphysis and diaphysis.
[Mh] Termos MeSH primário: Neoplasias Ósseas/metabolismo
Neoplasias Ósseas/secundário
Metaloproteinase 2 da Matriz/metabolismo
Metaloproteinase 9 da Matriz/metabolismo
Osteólise/metabolismo
Osteólise/patologia
[Mh] Termos MeSH secundário: Animais
Apoptose
Biomarcadores
Neoplasias Ósseas/patologia
Neoplasias da Mama/patologia
Linhagem Celular Tumoral
Modelos Animais de Doenças
Feminino
Xenoenxertos
Seres Humanos
Imuno-Histoquímica
Mamoglobina A/metabolismo
Metaloproteinase 13 da Matriz/metabolismo
Camundongos
Antígeno Nuclear de Célula em Proliferação/metabolismo
Fosfatase Ácida Resistente a Tartarato/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Mammaglobin A); 0 (Proliferating Cell Nuclear Antigen); 0 (SCGB2A2 protein, human); EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase); EC 3.4.24.- (Matrix Metalloproteinase 13); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.35 (Matrix Metalloproteinase 9)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160610
[St] Status:MEDLINE
[do] DOI:10.3892/mmr.2016.5374


  5 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27061528
[Au] Autor:Li C; Zhang T
[Ad] Endereço:Department of Pathology, Shandong University School of Medicine, Shandong, 250012, P.R. China.
[Ti] Título:Human mammaglobin: A specific marker for breast cancer prognosis.
[So] Source:J BUON;21(1):35-41, 2016 Jan-Feb.
[Is] ISSN:1107-0625
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:PURPOSE: In this study, we examined the expression of human mammaglobin (hMAM) mRNA and the protein levels in patients with breast cancer and their relationship with prognostic clinicopathological parameters. METHODS: hMAM mRNA expression in leucocytes from peripheral blood samples from patients diagnosed with primary invasive breast cancer (IC), carcinoma in situ (CIS), or benign breast diseases was analyzed using RT-PCR. The hMAM protein levels and expression patterns in tissue from 3 patient groups were evaluated by immunohistochemical staining, and several non-breast neoplasms were selected as negative controls, undergoing the same examination. RESULTS: The expression of hMAM mRNA was significantly higher in patients with IC or CIS compared to those with benign tumors (both<0.01). Immunohistochemical staining revealed similar results, where patients with IC or CIS had higher levels of hMAM protein (p<0.01 and p<0.01, respectively), while none of the negative controls expressed hMAM. Further analyses showed a strong correlation between hMAM protein/mRNA expression and clinicopathological factors, such as histological grade, clinical stage, and lymph node status, in patients with IC. CONCLUSION: The hMAM mRNA and protein expression profiles validate the potential of hMAM as a specific marker for breast cancer diagnosis and target treatment delivery.
[Mh] Termos MeSH primário: Neoplasias da Mama/química
Mamoglobina A/genética
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/análise
Neoplasias da Mama/patologia
Carcinoma in Situ/química
Feminino
Seres Humanos
Imuno-Histoquímica
Mamoglobina A/análise
Prognóstico
RNA Mensageiro/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Mammaglobin A); 0 (RNA, Messenger); 0 (SCGB2A2 protein, human)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:160709
[Lr] Data última revisão:
160709
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160411
[St] Status:MEDLINE


  6 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26970135
[Au] Autor:Wojtowicz ME; Dunn BK; Umar A
[Ad] Endereço:Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: wojtowim@mail.nih.gov.
[Ti] Título:Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.
[So] Source:Semin Oncol;43(1):161-172, 2016 Feb.
[Is] ISSN:1532-8708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The potential of the immune system to recognize and reject tumors has been investigated for more than a century. However, only recently impressive breakthroughs in cancer immunotherapy have been seen with the use of checkpoint inhibitors. The experience with various immune-based strategies in the treatment of late cancer highlighted the importance of negative impact advanced disease has on immunity. Consequently, use of immune modulation for cancer prevention rather than therapy has gained considerable attention, with many promising results seen already in preclinical and early clinical studies. Although not without challenges, these results provide much excitement and optimism that successful cancer immunoprevention could be within our reach. In this review we will discuss the current state of predominantly primary and secondary cancer immunoprevention, relevant research, potential barriers, and future directions.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/imunologia
Neoplasias da Mama/imunologia
Neoplasias da Mama/prevenção & controle
Neoplasias Colorretais/imunologia
Neoplasias Colorretais/prevenção & controle
Imunoterapia
Neoplasias Pancreáticas/imunologia
[Mh] Termos MeSH secundário: Imunidade Adaptativa
Animais
Autoantígenos/imunologia
Neoplasias Colorretais/genética
Feminino
Mutação da Fase de Leitura
Vacinas contra Hepatite B/uso terapêutico
Seres Humanos
Imunidade Inata
Vigilância Imunológica
Lactalbumina/imunologia
Mamoglobina A/imunologia
Vacinas contra Papillomavirus/uso terapêutico
Receptor ErbB-2/imunologia
Telomerase/antagonistas & inibidores
Telomerase/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Autoantigens); 0 (Hepatitis B Vaccines); 0 (Mammaglobin A); 0 (Papillomavirus Vaccines); 9013-90-5 (Lactalbumin); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); EC 2.7.7.49 (TERT protein, human); EC 2.7.7.49 (Telomerase)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170727
[Lr] Data última revisão:
170727
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160313
[St] Status:MEDLINE


  7 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26915653
[Au] Autor:Nazarkina ZhK; Khar'kova MV; Antonets DV; Morozkin ES; Bazhan SI; Karpenko LI; Vlasov VV; Ilyichev AA; Laktionov PP
[Ad] Endereço:Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. zha_naz@niboch.nsc.ru.
[Ti] Título:Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells.
[So] Source:Bull Exp Biol Med;160(4):486-90, 2016 Feb.
[Is] ISSN:1573-8221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Polyepitope DNA vaccine inducing T-cell-mediated immune response against cancer-specific antigens is a promising tool for selective elimination of tumor cells. Breast cancer-specific polyepitope DNA vaccine was designed using TEpredict and PolyCTLDesigner software on the basis of immunogenic peptides of HER2 and Mammaglobin-1 (Mam) tumor antigens. LPS-free preparations of plasmid DNA encoding polyepitope T-cell antigen and full-length copies of HER2 and Mam antigens were obtained. TaqMan-PCR systems for evaluation of the expression of immunogens in cells were created. The protocol of vaccine DNA delivery into dendritic cells was optimized. Expression of the target immunogens in dendritic cells derived from human peripheral blood mononuclear fraction after transfection with plasmid DNA preparations is demonstrated.
[Mh] Termos MeSH primário: Neoplasias da Mama/imunologia
Vacinas Anticâncer/imunologia
Células Dendríticas/imunologia
Mamoglobina A/imunologia
Receptor ErbB-2/imunologia
Receptores de Antígenos de Linfócitos T/imunologia
Linfócitos T Citotóxicos/imunologia
Vacinas de DNA/imunologia
[Mh] Termos MeSH secundário: Neoplasias da Mama/prevenção & controle
Linhagem Celular Tumoral
Células HEK293
Seres Humanos
Imunoterapia/métodos
Interleucina-10/biossíntese
Interleucina-6/biossíntese
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (IL10 protein, human); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Mammaglobin A); 0 (Receptors, Antigen, T-Cell); 0 (SCGB2A2 protein, human); 0 (Vaccines, DNA); 130068-27-8 (Interleukin-10); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160227
[St] Status:MEDLINE
[do] DOI:10.1007/s10517-016-3203-y


  8 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26851089
[Au] Autor:Abramczyk H; Brozek-Pluska B
[Ad] Endereço:Lodz University of Technology, Institute of Applied Radiation Chemistry, Laboratory of Laser Molecular Spectroscopy, Wroblewskiego 15, 93-590 Lodz, Poland. Electronic address: abramczy@mitr.p.lodz.pl.
[Ti] Título:New look inside human breast ducts with Raman imaging. Raman candidates as diagnostic markers for breast cancer prognosis: Mammaglobin, palmitic acid and sphingomyelin.
[So] Source:Anal Chim Acta;909:91-100, 2016 Feb 25.
[Is] ISSN:1873-4324
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Looking inside the human body fascinated mankind for thousands of years. Current diagnostic and therapy methods are often limited by inadequate sensitivity, specificity and spatial resolution. Raman imaging may bring revolution in monitoring of disease and treatment. The main advantage of Raman imaging is that it gives spatial information about various chemical constituents in defined cellular organelles in contrast to conventional methods (liquid chromatography/mass spectrometry, NMR, HPLC) that rely on bulk or fractionated analyses of extracted components. We demonstrated how Raman imaging can drive the progress on breast cancer just unimaginable a few years ago. We looked inside human breast ducts answering fundamental questions about location and distribution of various biochemical components inside the lumen, epithelial cells of the duct and the stroma around the duct during cancer development. We have identified Raman candidates as diagnostic markers for breast cancer prognosis: carotenoids, mammaglobin, palmitic acid and sphingomyelin as key molecular targets in ductal breast cancer in situ, and propose the molecular mechanisms linking oncogenes with lipid programming.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Neoplasias da Mama/diagnóstico
Carcinoma Ductal de Mama/diagnóstico
Mamoglobina A/análise
Ácido Palmítico/análise
Análise Espectral Raman
Esfingomielinas/análise
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Mammaglobin A); 0 (Sphingomyelins); 2V16EO95H1 (Palmitic Acid)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160207
[St] Status:MEDLINE


  9 / 223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26768031
[Au] Autor:Gown AM; Fulton RS; Kandalaft PL
[Ad] Endereço:PhenoPath Laboratories, Seattle, WA, USA.
[Ti] Título:Markers of metastatic carcinoma of breast origin.
[So] Source:Histopathology;68(1):86-95, 2016 Jan.
[Is] ISSN:1365-2559
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This review summarizes the three major breast-associated markers that can be of assistance in evaluating metastatic carcinomas for which a breast primary diagnosis is entertained. These markers include gross cystic disease fluid protein-15 (GCDFP-15), mammaglobin, and GATA3. The first two are cytoplasmic markers that show comparable sensitivities for breast cancer, although relatively few of the published studies have employed the same antibodies against the target molecule, making direct comparisons challenging. GATA3 is a nuclear transcription factor that shows superior sensitivity to GCDFP-15 and mammaglobin. However, the specificity of GATA3 can pose challenges, inasmuch as carcinomas of the bladder and other sites can show significant levels of positivity. Determination of the optimal panel of antibodies employed in a given clinical setting will thus depend on the non-breast tumours included in the differential diagnosis.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/patologia
Carcinoma/secundário
[Mh] Termos MeSH secundário: Neoplasias da Mama/metabolismo
Carcinoma/metabolismo
Proteínas de Transporte/metabolismo
Feminino
Fator de Transcrição GATA3/metabolismo
Glicoproteínas/metabolismo
Seres Humanos
Mamoglobina A/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (GATA3 Transcription Factor); 0 (GATA3 protein, human); 0 (Glycoproteins); 0 (Mammaglobin A); 0 (PIP protein, human)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160116
[St] Status:MEDLINE
[do] DOI:10.1111/his.12877


  10 / 223 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26447897
[Au] Autor:Kandalaft PL; Simon RA; Isacson C; Gown AM
[Ad] Endereço:*The PhenoPath Laboratories PLLC †Pacific Pathology Partners ‡CellNetix Pathology and Laboratories, Seattle, WA.
[Ti] Título:Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
[So] Source:Appl Immunohistochem Mol Morphol;24(9):609-614, 2016 Oct.
[Is] ISSN:1533-4058
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:GATA-3 is a transcription factor that has recently been identified by immunohistochemistry to be highly expressed in urothelial and breast carcinomas (CAs). We sought to determine the potential utility of GATA-3 in identifying metastatic breast CA, and to compare its utility with the standard breast markers, GCDFP-15, and mammaglobin A. We identified an archival series of 338 formalin-fixed paraffin-embedded whole-tissue sections of various CAs. Using standard immunohistochemical (IHC) techniques we used mouse monoclonal antibodies to GATA-3 (clones L50-823, HG3-31), GCDFP-15 (23A3), and mammaglobin A (31A5). Both clones of GATA-3 showed positivity in 96% of non-triple-negative breast carcinomas (TNBCs), L50-823 and HG3-31, demonstrating expression in 87% and 63% of TNBCs, respectively; GCDFP-15 and mammaglobin A were expressed in 69% and 61% of non-TNBCs, respectively, and 10% and 17%, of TNBCs, respectively. The L50-823 clone manifested a lower specificity in identifying breast CAs (84%) than did the HG3-31 clone (97%). Both monoclonal antibodies to GATA-3 are very sensitive reagents for the identification of breast CA, surpassing antibodies to GCDFP-15 and mammaglobin A, and offer a significant improvement in identifying TNBCs. However, the L50-823 clone showed a lower level of specificity, which may qualify its utility in the setting of CAs of unknown primary.
[Mh] Termos MeSH primário: Especificidade de Anticorpos
Biomarcadores Tumorais/imunologia
Neoplasias da Mama/imunologia
Proteínas de Transporte/imunologia
Fator de Transcrição GATA3/imunologia
Glicoproteínas/imunologia
Mamoglobina A/imunologia
[Mh] Termos MeSH secundário: Neoplasias da Mama/patologia
Feminino
Formaldeído
Seres Humanos
Imuno-Histoquímica
Inclusão em Parafina
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (GATA3 Transcription Factor); 0 (GATA3 protein, human); 0 (Glycoproteins); 0 (Mammaglobin A); 0 (PIP protein, human); 1HG84L3525 (Formaldehyde)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170802
[Lr] Data última revisão:
170802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151009
[St] Status:MEDLINE



página 1 de 23 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde